Clinical policies aim to prevent avoidable harm to patients by only offering treatments on the NHS that are evidence-based, clinically safe and effective, as well as cost effective and a good use of resources.
Currently there is not a single clinical policy for botulinum toxin for hyperhidrosis that applies to people across the whole Central East area.
Where a legacy Integrated Care Board (ICB) had an agreed clinical policy on botulinum toxin for hyperhidrosis, this policy transferred to Central East ICB on 1 April 2026. Previously agreed policies will continue to apply only to people living in that former ICB’s area until any new policy is adopted by NHS Central East ICB.
Where an area doesn’t have a previously agreed policy on botulinum toxin for hyperhidrosis, support for patients in that area will be based on a routine commissioning pathway.